Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hypercalciuria].

J Kocián1

  • 1Institut pro dalsí vzdĕlávání lékarů a farmaceutů Praha.

Vnitrni Lekarstvi
|July 1, 1992
PubMed
Summary

Hypercalciuria causes nearly 20% of secondary osteoporosis cases, often linked to kidney stones. Early detection and treatment with hydrochlorothiazide and amiloride offer effective management for bone demineralization.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Treatment osteoporosis 1999].

Vnitrni lekarstvi·2005
Same author

[Renaissance of fluorides and calcium in the treatment of osteoporosis].

Vnitrni lekarstvi·2000
Same author

[Treatment of Crohn's disease].

Casopis lekaru ceskych·1999
Same author

[Current views on the development and course of Crohn's disease].

Casopis lekaru ceskych·1999
Same author

[Bone demineralization in Crohn's disease, its diagnosis, therapy and prevention].

Casopis lekaru ceskych·1999
Same author

[Changes in cellular immunity after administration of nucleotides].

Casopis lekaru ceskych·1999

Area of Science:

  • Nephrology
  • Endocrinology
  • Bone Metabolism

Context:

  • Hypercalciuria is a significant factor in secondary osteoporosis.
  • Approximately 23% of hypercalciuria cases are associated with calcium urolithiasis.
  • Identifying and treating hypercalciuria is crucial for managing bone demineralization.

Purpose:

  • To highlight the prevalence and impact of hypercalciuria in secondary osteoporosis.
  • To emphasize the need for active screening of patients with osteoporosis for hypercalciuria.
  • To advocate for prompt and effective treatment of hypercalciuria.

Summary:

  • Hypercalciuria contributes to nearly 20% of secondary osteoporosis cases.
  • A substantial portion of these cases (23%) also present with calcium urolithiasis.
  • Treatment with hydrochlorothiazide and amiloride is effective and straightforward.
  • Multiple contributing factors to bone demineralization should be considered in each patient.
  • Treatment for osteopenia associated with hypercalciuria is generally shorter and more successful.

Impact:

  • Facilitates earlier diagnosis and intervention for secondary osteoporosis.
  • Improves patient outcomes through targeted and effective therapeutic strategies.
  • Reduces the complexity and duration of treatment for osteopenia.
  • Enhances the understanding of multifactorial bone demineralization.

Related Experiment Videos